Compare NC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | SLN |
|---|---|---|
| Founded | 1913 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.1M | 318.4M |
| IPO Year | N/A | N/A |
| Metric | NC | SLN |
|---|---|---|
| Price | $46.59 | $6.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 12.7K | ★ 279.0K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $280,838,000.00 | $25,830,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.46 | ★ N/A |
| Revenue Growth | 25.35 | ★ 40.39 |
| 52 Week Low | $27.47 | $1.97 |
| 52 Week High | $53.88 | $8.88 |
| Indicator | NC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 54.17 |
| Support Level | $43.71 | $5.98 |
| Resistance Level | $49.92 | $7.43 |
| Average True Range (ATR) | 2.34 | 0.54 |
| MACD | -0.31 | 0.02 |
| Stochastic Oscillator | 41.90 | 61.42 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.